Has Michael Loughner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $32,346 in general payments to Michael Loughner, MD across 1,067 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Loughner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Loughner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Loughner, MD

Endocrinology, Diabetes & Metabolism · Denver, CONPI 1639216906

Payments from drug & device makers

$32,346in general payments, 2019–2025

Across 1,067 payments — averaging $30.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$12K
AstraZeneca$6K
Antares Pharma, Inc.$2K
Amneal Pharmaceuticals LLC$2K
Amgen$1K
Novo Nordisk$1K
plus $8K from 47 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	51	$11,901
AstraZeneca(2 entities)	64	$6,125
Antares Pharma, Inc.	203	$2,300
Amneal Pharmaceuticals LLC	99	$1,528
Amgen(2 entities)	88	$1,477
Novo Nordisk	109	$1,366
Lilly USA, LLC	82	$1,189
Sanofi-aventis U.S. LLC	74	$1,053
Medtronic(2 entities)	38	$689
IBSA Pharma Inc.	32	$473
Mannkind Corporation	26	$424
Dexcom, Inc.	19	$261
Boehringer Ingelheim	14	$256
Radius Health, Inc.	12	$242
Amphastar Pharmaceuticals, Inc.	5	$224
Johnson & Johnson	13	$219
Abbott	12	$210
Cequr Corporation	3	$188
Recordati_rare_diseases_inc.	8	$186
Halozyme Inc	17	$178
Merck	10	$161
Tandem Diabetes Care, Inc.	6	$131
Insulet Corporation	8	$121
Kyowa Kirin, Inc.	5	$121
BETA Bionics, Inc.	6	$111
Bayer	6	$110
Ascendis Pharma Endocrinology Inc	4	$83
Valeritas, Inc.	5	$78
Kowa Pharmaceuticals America, Inc.	5	$76
Alvogen Inc	3	$76
Xeris Pharmaceuticals, Inc.	4	$76
Ipsen Biopharmaceuticals, Inc	3	$68
Novartis	3	$67
GRT US Holding, Inc.	3	$62
Corcept Therapeutics	3	$58
Ultragenyx Pharmaceutical Inc.	3	$53
Senseonics, Incorporated	2	$40
Pfizer	2	$36
Amarin Pharma, Inc.	2	$33
Acerus Pharmaceuticals Corporation	2	$33
Neurocrine Biosciences, Inc.	1	$33
Boston Scientific	1	$30
Lifescan, Inc.	1	$26
Sequel Med Tech, LLC	1	$25
Clarus Therapeutics Inc.	1	$22
BD	1	$21
EUSA Pharma (US) LLC	1	$20
Esperion Therapeutics, Inc.	1	$18
Ascensia Diabetes Care US Inc.	1	$17
Companion Medical, Inc.	1	$13
Aytu Biopharma, Inc.	1	$13
Zealand Pharma US, Inc.	1	$11
Amryt Pharma Holdings Ltd	1	$11

How this compares

$32,346 in reported general payments places this provider in the 75th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado →

Medicare billing

Part B allowed, 2024

$210,564

Medicare patients

697

Services billed

2,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Denver

Daniel BessesenDenver$1.2M
Leonard ZemelDenver$728K
Joshua KlopperDenver$48K
Alex GoldsmithDenver$12K
Daniel CitronDenver$8K
Sarah BullDenver$4K
Leslie GamacheDenver$4K
Claudia PanzerDenver$3K
Sheila MaierDenver$2K
Karin HickeyDenver$2K

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →